Reports Q4 cash, cash equivalents and investments as of December 31 were $441.2M. In addition, as of December 31 cash receivables from the Company’s collaborations with Janssen and ONO were $38.5M, which includes $22.5M from the exercise of certain options and $3.0 million from the achievement of a regulatory milestone during the fourth quarter of 2022. revenue $, consensus $."We have focused our operations on advancing our most innovative and differentiated programs for patients with cancer and autoimmune disorders, and we have substantially reduced our expenses with the intent of providing the necessary cash runway to achieve key clinical milestones across our multiplexed-engineered, iPSC-derived CAR NK and CAR T-cell product candidates," said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. "We are now enrolling multi-dose treatment cohorts with FT576 for multiple myeloma, including in combination with CD38-targeted monoclonal antibody therapy to promote dual-antigen targeting and selective depletion of activated host immune cells. We also plan to submit an IND application in the middle of 2023 for FT522, which incorporates our proprietary ADR technology designed to enable patient dosing with reduced conditioning chemotherapy, and intend to initiate clinical development in B-cell lymphoma with plans to expand clinical investigation to severe autoimmune disorders. In addition, we are excited with the progress of our iPSC-derived CAR T-cell pipeline for the treatment of hematologic malignancies and solid tumors. Dose escalation is continuing in our landmark Phase 1 study of FT819, with interim clinical data showing a favorable safety profile and demonstrating complete responses in heavily pre-treated patients with aggressive B-cell lymphoma. Finally, we plan to submit an IND application in 2023 for FT825/ONO-8250 under our collaboration with ONO Pharmaceutical, which incorporates seven novel synthetic controls designed to more effectively attack solid tumors."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FATE:
- Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
- Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
- Fate Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Fly Insider: Coinbase, Buckle among week’s notable insider trades
- Fate Therapeutics price target lowered to $16 from $42 at Canaccord